LU91356I2 - Traitement de diabete a l'aide de thiazolidinedione et de metformine - Google Patents

Traitement de diabete a l'aide de thiazolidinedione et de metformine

Info

Publication number
LU91356I2
LU91356I2 LU91356C LU91356C LU91356I2 LU 91356 I2 LU91356 I2 LU 91356I2 LU 91356 C LU91356 C LU 91356C LU 91356 C LU91356 C LU 91356C LU 91356 I2 LU91356 I2 LU 91356I2
Authority
LU
Luxembourg
Prior art keywords
thiazolidinedione
metformin
diabetes treatment
diabetes
treatment
Prior art date
Application number
LU91356C
Other languages
English (en)
French (fr)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91356(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712857.3A external-priority patent/GB9712857D0/en
Priority claimed from GBGB9806706.9A external-priority patent/GB9806706D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of LU91356I2 publication Critical patent/LU91356I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
LU91356C 1997-06-18 2007-08-29 Traitement de diabete a l'aide de thiazolidinedione et de metformine LU91356I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9712857.3A GB9712857D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806706.9A GB9806706D0 (en) 1998-03-27 1998-03-27 Novel method
PCT/EP1998/003690 WO1998057634A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and metformin

Publications (1)

Publication Number Publication Date
LU91356I2 true LU91356I2 (fr) 2008-01-29

Family

ID=26311745

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91356C LU91356I2 (fr) 1997-06-18 2007-08-29 Traitement de diabete a l'aide de thiazolidinedione et de metformine

Country Status (38)

Country Link
US (3) US20060100247A1 (enEXAMPLES)
EP (2) EP1787646A3 (enEXAMPLES)
JP (1) JP2002504137A (enEXAMPLES)
KR (2) KR20060105005A (enEXAMPLES)
CN (2) CN1230171C (enEXAMPLES)
AP (1) AP1279A (enEXAMPLES)
AR (2) AR012995A1 (enEXAMPLES)
AT (1) ATE355840T1 (enEXAMPLES)
AU (1) AU8539398A (enEXAMPLES)
BG (2) BG64818B1 (enEXAMPLES)
BR (1) BR9810172A (enEXAMPLES)
CA (1) CA2294582C (enEXAMPLES)
CY (2) CY1107643T1 (enEXAMPLES)
CZ (1) CZ298469B6 (enEXAMPLES)
DE (2) DE69837261T2 (enEXAMPLES)
DK (1) DK0996444T3 (enEXAMPLES)
DZ (1) DZ2520A1 (enEXAMPLES)
EA (1) EA003144B1 (enEXAMPLES)
ES (1) ES2284212T3 (enEXAMPLES)
ID (1) ID23372A (enEXAMPLES)
IL (3) IL133142A0 (enEXAMPLES)
IN (1) IN189722B (enEXAMPLES)
LU (1) LU91356I2 (enEXAMPLES)
MA (1) MA26512A1 (enEXAMPLES)
MY (1) MY129897A (enEXAMPLES)
NL (1) NL300288I2 (enEXAMPLES)
NO (4) NO324993B1 (enEXAMPLES)
NZ (1) NZ501260A (enEXAMPLES)
OA (1) OA11516A (enEXAMPLES)
PE (1) PE83199A1 (enEXAMPLES)
PL (2) PL195140B1 (enEXAMPLES)
PT (1) PT996444E (enEXAMPLES)
SI (1) SI0996444T1 (enEXAMPLES)
SK (1) SK286029B6 (enEXAMPLES)
TR (1) TR199903057T2 (enEXAMPLES)
TW (1) TW565449B (enEXAMPLES)
UY (1) UY25049A1 (enEXAMPLES)
WO (1) WO1998057634A1 (enEXAMPLES)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2158607C2 (ru) * 1995-07-03 2000-11-10 Санкио Компани Лимитед Лечение артериосклероза и ксантомы
GB9712857D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
ES2206868T3 (es) 1998-07-15 2004-05-16 Merck Sante Comprimidos que comprenden una combinacion de metformin glibenclamida.
WO2000053171A1 (en) * 1999-03-05 2000-09-14 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
AR023564A1 (es) 1999-04-23 2002-09-04 Smithkline Beecham Plc Una forma polimorfica de sal del acido maleico derivado del tiazolidina-2,4 diona, una composicion farmaceutica y el uso del mismo para la fabricacion deun medicamento
CN1450902A (zh) 1999-11-03 2003-10-22 布里斯托尔-迈尔斯斯奎布公司 包含二甲双胍和格列本脲组合的药用组合物
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
WO2001035940A2 (en) * 1999-11-16 2001-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
EP1278513B1 (en) * 2000-05-01 2007-07-18 Aeropharm Technology, LLC A core formulation
FR2812547B1 (fr) * 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
WO2002055009A1 (en) 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
ES2529180T3 (es) * 2002-09-20 2015-02-17 Andrx Labs Llc Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
AU2004208606B2 (en) 2003-01-29 2009-09-24 Takeda Pharmaceutical Company Limited Process for producing coated preparation
CA2562391A1 (en) 2004-04-14 2005-10-27 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
JPWO2006011397A1 (ja) * 2004-07-27 2008-05-01 興和株式会社 糖尿病の予防または治療のための薬剤
US20070032420A1 (en) * 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
CA2615118A1 (en) * 2005-07-12 2007-01-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ppar.gamma. agonist
ES2294980T1 (es) * 2006-05-09 2008-04-16 Teva Pharmaceutical Industries Ltd. Acido 2-n-(5-((4-(2-(metil-2-piridinilamino)etoxi)fenil)metil)-2,4-tiazolidindiona)-butanodioico, procedimientos de preparacion y composiciones con maleato de rosiglitazona.
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
CN101069745B (zh) * 2006-05-12 2010-07-21 北京华安佛医药研究中心有限公司 治疗2型糖尿病的药物组合物
US7919410B2 (en) * 2007-03-14 2011-04-05 Aptina Imaging Corporation Packaging methods for imager devices
CN102137836B (zh) * 2008-07-28 2015-08-26 赛丹思科大学 用于治疗代谢疾病的化合物
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
JP2014501787A (ja) 2011-01-07 2014-01-23 エルセリクス セラピューティクス インコーポレイテッド 化学感覚受容体リガンドに基づく治療法
BR112014016808B1 (pt) 2012-01-06 2022-01-11 Anji Pharma (Us) Llc Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose
SG11201403873UA (en) 2012-01-06 2014-08-28 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) * 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
JPH06510286A (ja) * 1991-08-26 1994-11-17 ファルマシア・アンド・アップジョン・カンパニー ３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
EP0832066B1 (en) * 1995-06-06 2001-09-12 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JPH09270635A (ja) * 1996-04-01 1997-10-14 Honda Motor Co Ltd 平面アンテナモジュール
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US20020177612A1 (en) * 1997-06-05 2002-11-28 Smithkline Beecham P.I.C. Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
JP4278863B2 (ja) * 1997-12-08 2009-06-17 ブリストル−マイヤーズ スクイブ カンパニー メトホルミンの新規塩および方法
EP1555845A1 (de) * 2004-01-15 2005-07-20 Siemens Aktiengesellschaft Verfahren zur Positionsbestimmung von Teilnehmerstationen eines Funkkommunikationssystems

Also Published As

Publication number Publication date
NO20090846L (no) 1999-12-17
MY129897A (en) 2007-05-31
EP0996444A1 (en) 2000-05-03
AR012998A1 (es) 2000-11-22
AP1279A (en) 2004-05-20
CA2294582A1 (en) 1998-12-23
PL195140B1 (pl) 2007-08-31
NO2008003I1 (no) 2008-04-21
CN1260716A (zh) 2000-07-19
NO324993B1 (no) 2008-01-14
NZ501260A (en) 2002-09-27
BR9810172A (pt) 2000-08-08
US20080090881A1 (en) 2008-04-17
SI0996444T1 (sl) 2007-08-31
NO996266L (no) 1999-12-17
CZ298469B6 (cs) 2007-10-10
IN189722B (enEXAMPLES) 2003-04-19
BG104060A (en) 2000-10-31
AP9901719A0 (en) 1999-12-31
MA26512A1 (fr) 2004-12-20
US20070004780A1 (en) 2007-01-04
ATE355840T1 (de) 2007-03-15
OA11516A (en) 2004-02-04
NO326958B1 (no) 2009-03-23
SK286029B6 (sk) 2008-01-07
CN1429551A (zh) 2003-07-16
CY2007018I1 (el) 2012-01-25
KR20060105005A (ko) 2006-10-09
JP2002504137A (ja) 2002-02-05
PE83199A1 (es) 1999-10-22
BG64818B1 (bg) 2006-05-31
SK179299A3 (en) 2000-11-07
TW565449B (en) 2003-12-11
NO996266D0 (no) 1999-12-17
IL133142A (en) 2006-06-11
CN1230171C (zh) 2005-12-07
DE69837261T2 (de) 2007-11-08
IL133142A0 (en) 2001-03-19
KR100666591B1 (ko) 2007-01-11
AR012995A1 (es) 2000-11-22
NL300288I1 (nl) 2007-11-01
US20060100247A1 (en) 2006-05-11
ID23372A (id) 2000-04-20
ES2284212T3 (es) 2007-11-01
CN1114404C (zh) 2003-07-16
CA2294582C (en) 2008-02-12
DZ2520A1 (fr) 2003-02-01
UY25049A1 (es) 2000-09-29
NL300288I2 (nl) 2009-06-02
PL195136B1 (pl) 2007-08-31
DE122007000054I1 (de) 2007-12-13
EP1787646A2 (en) 2007-05-23
AU8539398A (en) 1999-01-04
CZ9904578A3 (en) 2001-06-13
TR199903057T2 (xx) 2000-04-21
NO2008003I2 (no) 2010-06-28
IL173650A0 (en) 2006-07-05
WO1998057634A1 (en) 1998-12-23
DK0996444T3 (da) 2007-07-02
CY1107643T1 (el) 2012-01-25
EA003144B1 (ru) 2003-02-27
PT996444E (pt) 2007-06-08
EP0996444B1 (en) 2007-03-07
EP1787646A3 (en) 2007-10-03
DE69837261D1 (de) 2007-04-19
KR20010013844A (ko) 2001-02-26
NO20063000L (no) 1999-12-17
HK1028193A1 (en) 2001-02-09
BG109398A (bg) 2006-05-31
PL337362A1 (en) 2000-08-14
EA200000041A1 (ru) 2000-08-28

Similar Documents

Publication Publication Date Title
LU91356I2 (fr) Traitement de diabete a l'aide de thiazolidinedione et de metformine
DE69417753D1 (de) Wegwerfbare monatsunterhose
FR13C0016I2 (fr) Anticorps anti-erbb2 humanises et traitement a l'aide de ces anticorps
HUP0001393A3 (en) Oxazolidinone antibacterial agents having a thiocarbonyl-functionality and their medical use
FI20000038L (fi) Tiadiatsolyyli- ja oksadiatsolyylifenyylioksatsolidinonit antibakteerisina aineina
PT775126E (pt) 1,1-dioxidos de 1,4-benzotiazepina hipolipidemica
FI904414A7 (fi) Tiatsolidiinidioni-hypoglykeemisesti vaikuttavat aineet
IS5252A (is) 4'' -setnar - 9 - deoxo - 9 - aza - 9a - homoerythromys¡n A afleithur
FI964060A0 (fi) Kosketusjousi
PT1017408E (pt) Utilizacao de tetra-hidrolipstatina no tratamento de diabetes de tipo ii
DE69636506D1 (de) Antibakterielle und fungizide Kette
DE69817795D1 (de) Polydextrose als haltbarkeitszusatz
FR2650175B1 (fr) Orthese poignet-pouce de rhizarthrose
MA23202A1 (fr) Agents d'arylation
FR2784983B1 (fr) Amenagement d'espaces de baignade a epuration biologique
BR9304037A (pt) Composiçâo germicida e sabonete a mesma
FR2660860B1 (fr) Aiguille d'acupuncture a usage unique.
FR2663361B1 (fr) Fut, notamment pour candelabre d'eclairage public, et mecanisme d'articulation adapte a relier une porte de visite au reste du fut.
KR960030540U (ko) 보울링용 손목 보호대
KR960010047U (ko) 볼리용 손목 보호대
DE69424171D1 (de) Analog Fuzzy-Logik-Prozessor
FR2773145B1 (fr) Perfectionnements apportes au traitement physico-chimique d'effluents
BR9303544A (pt) Babador descartável
ITMI941206A1 (it) Macrolidi ad attivita' antibatterica
SK765U (sk) Dezinfekčný a čistiaci roztok